Ultragenyx Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emil D. Kakkis
- Full Time Employees
- 1,371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Leveroni Court Novato CA United States of America 94949
- IPO Date
- Jan 31, 2014
- CIK
- 0001515673
- Website
- ultragenyx.com
- Similar Companies
- Business
- Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare and ultrarare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company offers approved products including Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii for mucopolysaccharidosis VII; and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders; alongside a robust pipeline targeting conditions such as Angelman syndrome with GTX-102. Ultragenyx operates globally, with commercial presence in North America, Europe, and select international markets, serving patients through specialized support programs like UltraCare. In recent developments, Ultragenyx sold a portion of future North American royalties on Crysvita to OMERS Life Sciences for $400 million in November 2025; reported third quarter 2025 financial results with total revenue guidance of $640 million to $670 million; dosed the first patient in the Aurora study for GTX-102 in Angelman syndrome in October 2025; and appointed Eric Olson as Chief Business Officer in September 2025.
LEADING EDGE MATERIALS ADVANCES MIDSTREAM PROCESSING STRATEGY FOR THE NORRA KÄRR HEAVY RARE EARTH ELEMENTS PROJECT
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect